MedPath

Effects of Pueraria mirifica gel on overactive bladder symptoms in postmenopausal wome

Phase 2
Conditions
Overactive bladder in menopausal women
Registration Number
TCTR20210825009
Lead Sponsor
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending (Not yet recruiting)
Sex
Female
Target Recruitment
60
Inclusion Criteria

No history of estrogen use in previous 3 month
- No history of medical treatment for OAB in previous 3 month
- No current UTI
- No postmenopausal bleeding with unknown diagnosis
- No contraindication for estrogen therapy such as breast cancer, ovarian cancer, VTE, active liver disease

Exclusion Criteria

- Patient deny
- Exist complication from Pueraria mirifica gel or placebo

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
OABSS at 12 week after intervention OABS score
Secondary Outcome Measures
NameTimeMethod
Quality of life after intervention at 12 week after intervention IIQ-7,Urethral maturation indexUrethral maturation at 12 week after intervention Urethral maturation indexUrethral maturation
© Copyright 2025. All Rights Reserved by MedPath